Company Overview of Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes in the United States. The company’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase 1a/1b clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase 1/2 clinical trial for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trial for the treatment of rheumatoid arthritis. Its product candidates also comprise FPA144, an antibody that inhibits fibroblast growth ...
Two Corporate Drive
South San Francisco, CA 94080
Founded in 2001
Key Executives for Five Prime Therapeutics, Inc.
Founder, Chairman, Chief Executive Officer and President
Total Annual Compensation: $525.0K
Chief Business Officer, Executive Vice President and Director
Total Annual Compensation: $383.5K
Executive Vice President, General Counsel and Secretary
Total Annual Compensation: $358.5K
Compensation as of Fiscal Year 2015.
Five Prime Therapeutics, Inc. Key Developments
Five Prime Therapeutics Announces Updated Clinical Data on FPA144 and FP-1039
May 18 16
Five Prime Therapeutics, Inc. announced that updated data from the ongoing clinical trials of FPA144 and FP-1039. Further data on safety and activity from the Phase 1 trial evaluating FPA144, an antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced, FGFR2b isoform-selective monoclonal antibody, as a single agent in patients with FGFR2b+ gastric cancer and advanced solid tumors will be featured in an oral presentation: ABSTRACT 2502. Antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody, in patients with FGFR2b+ gastric cancer and advanced solid tumors Oral Abstract Session: Developmental Therapeutics Clinical Pharmacology and Experimental Therapeutics. Preliminary dose escalation data from the FPA144 trial  were presented during the ASCO Gastrointestinal Cancers Symposium in January 2016. FPA144 is an anti-FGF receptor 2b (FGFR2b) humanized monoclonal antibody in clinical development as a targeted immune therapy for tumors that over-express FGFR2b, as determined by a proprietary immunohistochemistry (IHC) diagnostic assay. FGFR2 gene amplification (as identified by FISH) is found in a number of tumors, including in approximately 5% of gastric cancer patients, and is associated with poor prognosis. FPA144 is designed to block tumor growth through two distinct mechanisms. First, it has been engineered to drive immune-based killing of tumor cells by antibody-dependent cell-mediated cytotoxicity (ADCC) and the recruitment of natural killer (NK) cells and T cells. Second, it binds specifically to FGFR2b and prevents the binding of certain fibroblast growth factors that promote tumor growth. When combined with PD-1 blockade, FPA144 has shown an additive effect in tumor growth inhibition in preclinical models. Five Prime retains global development and commercialization rights to FPA144. FP-1039 is a protein drug designed to intervene in FGF signaling. As a ligand trap, FP-1039 binds to FGF ligands circulating in the extracellular space (such as FGF2), preventing these signaling proteins from reaching FGFR1 on the surface of tumor cells where they would otherwise stimulate cancer cell division and/or angiogenesis. However, FP-1039 does not bind to certain "hormonal" FGFs, including FGF-23, which regulates phosphate levels in the blood. Â As a result, treatment with FP-1039 treatment has not been shown to cause hyperphosphatemia, a side effect seen with small molecule inhibitors of FGF receptors, which block the activity of both cancer-associated FGFs and FGF-23.
Five Prime Therapeutics Advances FPA008 Into Phase 2 Dose Expansion in Patients with Pigmented Villonodular Synovitis
May 12 16
Five Prime Therapeutics, Inc. announced the advancement of FPA008 into the Phase 2 dose expansion portion of the ongoing Phase 1/2 trial in PVNS. Five Prime initiated patient dosing in this Phase 1/2 clinical trial of FPA008 in July 2015. During the Phase 1 dose escalation part of the trial, Five Prime assessed the safety and pharmacodynamics of multiple ascending doses of FPA008 to determine the dose for expansion. During the Phase 2 expansion, the company will evaluate response rate and duration, as well as measures of pain and range of motion, in approximately 30 patients. In January 2016, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for FPA008 for the treatment of PVNS, which is estimated to have a prevalence of 25,000 patients in the U.S.
Five Prime Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2016 Healthcare Conference, May-12-2016 10:00 AM
May 6 16
Five Prime Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2016 Healthcare Conference, May-12-2016 10:00 AM. Venue: The Encore at Wynn, 3131 S Las Vegas Blvd, Las Vegas, NV 89109, United States. Speakers: Lewis T. Williams, Founder, Chairman, Chief Executive Officer and President.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|